- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02749435
A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus
A Real-world, Point-of-care, Randomized, Parallel Group, Open, 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Fife, United Kingdom
- Research Site
-
Leicester, United Kingdom
- Research Site
-
London, United Kingdom
- Research Site
-
Mid Glamorgan, United Kingdom
- Research Site
-
Stockport, United Kingdom
- Research Site
-
-
Angus
-
Dundee, Angus, United Kingdom
- Research Site
-
-
Cardiff [Caerdydd GB-CRD]
-
Cardiff, Cardiff [Caerdydd GB-CRD], United Kingdom
- Research Site
-
-
Dundee City
-
Muirhead, Dundee City, United Kingdom
- Research Site
-
-
Flintshire [Sir y Fflint GB-FF
-
Flintshire, Flintshire [Sir y Fflint GB-FF, United Kingdom
- Research Site
-
-
Harrow
-
London, Harrow, United Kingdom
- Research Site
-
-
Lancashire
-
Manchester, Lancashire, United Kingdom
- Research Site
-
-
Manchester
-
Oldham, Manchester, United Kingdom
- Research Site
-
-
Midlothian
-
Bonnyrigg, Midlothian, United Kingdom
- Research Site
-
Edinburgh, Midlothian, United Kingdom
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
For inclusion in the study participants must fulfill the following criteria:
- Provision of written informed consent prior to any study-specific procedures.
- Female or male aged ≥18 years at time of consent.
- Diagnosed with T2DM.
- Treatment with one or more non-insulin antihyperglycaemic medication(s) for at least 6 months prior to enrolment
- Own/have access to a smart phone with internet access and have access to the internet via a tablet or personal computer at least once a day. At the HCP's discretion, a patient may be without access to their smart phone service, data connection, and internet access for a period of time that should be ≤2 consecutive weeks
- HbA1c levels ≥8.0% and ≤11.0% within the last 6 months. If more than 1 value is available during the 6-month time period, all values must be within this range
- Body mass index (BMI) ≥25 and ≤55 kg/m2 within the last 3 months
- Ability to communicate in English
- Judged by their HCP to have suitable hearing, vision, manual dexterity, ability to understand instructions, and ability to use and understand smart phone and internet applications
- Negative pregnancy test (urine or serum) for female patients of childbearing potential
Exclusion criteria:
Participants cannot enter the study if any of the following exclusion criteria are fulfilled:
- Pregnancy
- Insulin use at baseline
- Current use of a smart phone- or web portal-based tool to help with management of T2DM
- History of type I diabetes or ketoacidosis
- Currently taking a weight loss medication
- Involvement in the planning and/or conduct of the study (applies to both AZ staff and/or staff and affiliates at the study site)
- Previous enrolment in the present study
- Participation in a clinical study with an investigational product or a disease state management program during the last 30 days
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Standard of Care + digital disease management cohort
Participants will have access to the smart phone- and web portal-based digital disease management tool in addition to standard care.
|
The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control.
The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone.
All participants will complete the PRO assessments.
This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
|
Standard of Care cohort
Participants will have standard care with no access to the digital disease management tool.
|
The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control.
The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone.
All participants will complete the PRO assessments.
This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change from baseline to Month 6 in HbA1c
Time Frame: From Baseline to 6 months
|
The primary outcome measure is the mean change from baseline to Month 6 in HbA1c. Mean changes from baseline to intermediate visits (if any occur) will also be determined. Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants who achieve HbA1c levels <7% at Month 6
Time Frame: Month 6 of study participation
|
Proportion of participants who achieve HbA1c levels <7% at Month 6
|
Month 6 of study participation
|
Mean change in Body weight (kg) from baseline to Month 6
Time Frame: From Baseline to 6 months
|
Mean change in Body weight (kg) from baseline to Month 6. Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Proportion of patients in both cohorts who intensify antihyperglycaemic treatment from Visit 1
Time Frame: From Baseline to 6 months
|
Proportion of participants in both cohorts who intensify antihyperglycaemic treatment from Visit 1, defined as an increase in dose or addition of a new antihyperglycaemic agent not received at baseline. Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of times smart phone- and/or web portal-based tool accessed per patient
Time Frame: From Baseline to 6 months
|
Number of times smart phone- and/or web portal-based tool accessed per patient. Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Mean percent change from baseline to Month 6 in SBP
Time Frame: From Baseline to 6 months
|
Mean percent change from baseline to Month 6 in SBP. Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Proportion of patients who achieve BP <140/90 mmHg at Month 6
Time Frame: From Baseline to 6 months
|
Proportion of patients who achieve BP <140/90 mmHg at Month 6. Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Mean percent change from baseline to Month 6 in LDL-C
Time Frame: From Baseline to 6 months
|
Mean percent change from baseline to Month 6 in LDL-C. Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Proportion of patients who achieve LDL-C <100 mg/dL at Month 6
Time Frame: From Baseline to 6 months
|
Proportion of patients who achieve LDL-C <100 mg/dL at Month 6. Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Length of time from first to last usage of smart phone- and/or web portal-based tool
Time Frame: From Baseline to 6 months
|
Length of time from first to last usage of smart phone- and/or web portal-based tool. Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Mean difference in primary care office visits between active and control group during the 6-month study period as reported in patient records (to examine potential differences in resource utilization)
Time Frame: From Baseline to 6 months
|
Mean difference in primary care office visits between active and control group during the 6-month study period as reported in patient records (to examine potential differences in resource utilization). Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Mean difference in Emergency Room visits between active and control groupduring the 6-month study period as reported by patients at the end of the study (to examine potential differences in resource utilization)
Time Frame: From Baseline to 6 months
|
Mean difference in Emergency Room visits between active and control group during the 6-month study period as reported by patients at the end of the study (to examine potential differences in resource utilization). Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Change from baseline to Month 6 in Diabetes Treatment Satisfaction Questionnaire - Status version (DTSQs) score (8-question) (treatment satisfaction)
Time Frame: From Baseline to 6 months
|
Change from baseline to Month 6 in Diabetes Treatment Satisfaction Questionnaire - Status version (DTSQs) score (8-question) (treatment satisfaction). The Patient-reported outcomes (PROs) include DTSQs. The DTSQs (8-item scale) is a widely used instrument in diabetes in both clinical trials and routine clinical practice, to measure of treatment satisfaction. |
From Baseline to 6 months
|
Change from baseline to Month 6 in Diabetes Self-Management Questionnaire (DSMQ) score (16-question) (patient perception on ability to manage their disease)
Time Frame: From Baseline to 6 months
|
Change from baseline to Month 6 in Diabetes Self-Management Questionnaire (DSMQ) score (16-question) (patient perception on ability to manage their disease). The PROs include the DSMQ. The DSMQ is a 16-item questionnaire to assess self-care activities associated with glycaemic control in patients with diabetes. Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Change from baseline to Month 6 in Morisky 8-item scale (adherence)
Time Frame: From Baseline to 6 months
|
Change from baseline to Month 6 in Morisky 8-item scale (adherence). The PROs include the Morisky Scale. The Morisky Scale is an 8-item medication adherence questionnaire. Mean change from baseline to intermediate visits are optional and only occur if it is a part of standard of care. |
From Baseline to 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Manesh Saxena, Barts and the London, Queen Mary School of Medicine and Dentistry
- Principal Investigator: Deepak Bhatnagar, Penine Acute Hospitals Trust
- Principal Investigator: Aled Roberts, Cardiff and Vale NHS Trust - University Hospital of Wales
- Principal Investigator: Melanie Davies, Leicester General Hospital
- Principal Investigator: See Kwok, Barlow Medical Centre
- Principal Investigator: Keith Richardson, Bridge House Medical Centre
- Principal Investigator: Deborah Wake, Ninewells Hospital and Medical School
- Principal Investigator: Ruth Leese, Muirhead Medical Centre
- Principal Investigator: Neela Chatakondu, Marches Medical Practice
- Principal Investigator: Tom Hoyland, Ashgrove Surgery
- Principal Investigator: Allan Copland, Auchtermuchty Health Centre
- Principal Investigator: Calum MacKenzie, Loanhead Medical Practice
- Principal Investigator: Simon Barrett, Quarryfoot Medical Practice
- Principal Investigator: John Shewring, Llanderyn Health Centre
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D1841C00002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type II Diabetes Mellitus
-
KeyBioscience AGEli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...TerminatedType II Diabetes MellitusGermany
-
pico-tesla Magnetic Therapies, LLCCompletedType II Diabetes MellitusUnited States
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
HealthInsightCenter for Technology and Aging; VoxivaUnknownType II Diabetes MellitusUnited States
-
University of PretoriaNestlè Nutrition Institute Africa; South African Sugar AssociationCompletedDiabetes Mellitus, Type II [Non-insulin Dependent Type] [NIDDM Type] UncontrolledSouth Africa
-
University of PrimorskaUniversity of Ljubljana School of Medicine, SloveniaCompletedDiabetes Mellitus Type II,Slovenia
-
Microbio Co LtdCompleted
-
Laboratorios Silanes S.A. de C.V.RecruitingDyslipidemia Associated With Type II Diabetes MellitusMexico
-
EMSRecruitingDyslipidemia Associated With Type II Diabetes MellitusBrazil
Clinical Trials on Use of digital disease management tool in participants with T2DM
-
AstraZenecaCompletedType 2 Diabetes MellitusUnited States
-
University Hospital, Clermont-FerrandRecruitingHereditary Hemorrhagic Telangiectasia | Rendu Osler DiseaseFrance
-
Memorial Sloan Kettering Cancer CenterCompletedLymphedema | Ovarian Cancer | Vaginal Cancer | Uterine CancerUnited States
-
Pontificia Universidad Catolica de ChileUnknown
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...Enrolling by invitationHIV Infections | Opioid Use | Drug Use | Opioid-use DisorderUnited States
-
Central Hospital, Nancy, FranceRecruitingCardiovascular Diseases | Risk Factors | Nutrition | Cohort Studies | GenotypeFrance
-
University Medical Center GroningenBoehringer IngelheimNot yet recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Diabetes Complications | Chronic Kidney Diseases | Albuminuria | CKD | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | CKD Stage 4 | CKD Stage 3 | Chronic Kidney Disease Due to Type 2 Diabetes Mellitus | Diabetes Mellitus Type 2 With Proteinuria